Anogenital Psoriasis MedDRA version: 1 Level: LLT Classification code 10016776 Term:
Conditions
Interventions
Trade Name: Humira
Product Name: Humira
Pharmaceutical Form: Injection*
INN or Proposed INN: adalimumab
CAS Number: 331731-18-1
Current Sponsor code: ABT-D2E7
Other descriptive name: humira
Concentrat
Sponsors
Abbott
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient has moderate to severe anogenital psoriasis. Patient is over 18 years old. Patient is heterosexual. Treatment with adalimumab is to be started by attending dermatologist. Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: Patient is unwilling to participate. Patient is homosexual. Patient is younger than 18 years.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: To asses the effect of improvement of anogenital psoriasis on sexual function in patients treated with adalimumab.;Secondary Objective: To assess the psychosexual problems in a population of patients with anogenital psoriasis.;Primary end point(s): Reduction of PASI and questionnare scores. Reduction of scores in questionnares: -Skindex -PASI -SEAR -IIEF -FSF -HADS | — |
Countries
Netherlands
Outcome results
None listed